MIDTERM OUTCOME OF FEMOROFEMORAL CROSS OVER BYPASS GRAFTS

Article Sidebar

PDF
Published: Mar 6, 2024
Keywords:
Femorofemoral crossover Bypass Iliac artery vascular patency

Main Article Content

Dr Krishna Kant Sahu
Department of Cardiothoracic and Vascular Surgery (CTVS), Pt. Jawaharlal Nehru Memorial Medical College, Raipur, Chhattisgarh, India
Dr Nitin Kashyap
Department of Cardiothoracic and Vascular Surgery (CTVS), All India Institute of Medical Sciences, Raipur, Chhattisgarh, India
Dr.Nishant Chandel
Department of Cardiothoracic and Vascular Surgery (CTVS), Pt. Jawaharlal Nehru Memorial Medical College, Raipur, Chhattisgarh, India
Dr.Sattwashree Mandal
Department of General Surgery, Pt. Jawaharlal Nehru Memorial Medical College, Raipur, Chhattisgarh, India
Dr.Ayushi Shukla
Department of Neurology, DKS post graduate institute, Raipur, Chhattisgarh, India

Abstract

Background: Femorofemoral crossover bypass (FCB) is a procedure for patients with unilateral iliac artery disease. Our goal was to assess mid-term patency of graft used in FCB.


 Methods: A retrospective review from a single centre of consecutive patients who underwent Femorofemoral crossover bypass from November 2017 to February 2021 was done. Data was collected from hospital records and follow-up done up to February 2022.  We have analysed the graft material used, size of graft and operative procedures.


 Results: The indications for FCB were claudication in 42 and critical limb ischemia in 10 patients. The 1-month patency rate is 100%, 3 month patency rate is 96%, 6 month patency rate is 94% and 1 year patency rate is 90%.


 Conclusion: Our mid-term analysis suggests that FCB might be a valuable alternative treatment modality in patients with unilateral iliac artery disease.

Article Details

Issue
Vol. 57 No. 1 (2024): Pakistan Heart Journal
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.